CETP与PCSK9联合基因抑制与冠心病风险的析因孟德尔随机化研究
结果显示,按每降低10 mg/dL LDL-C计算,CETP与PCSK9降低对冠心病的关联相似;联合暴露对血脂和所有结局呈相加效应,未观察到非相加交互作用,尤其LDL-C和冠心病。
要点
- 按每10 mg/dL LDL-C降低计,CETP与PCSK9降低对冠心病风险关联相似。
- 联合降低CETP和PCSK9对LDL-C及冠心病风险呈相加效应,无显著交互。
- CETP降低与年龄相关性黄斑变性风险增加相关(多重检验校正后)。
核心结论
- 联合抑制CETP和PCSK9对血脂指标和疾病风险(包括冠心病风险降低)具有相加效应。
- CETP与PCSK9降低对冠心病的关联在按每10 mg/dL LDL-C降低缩放时相似。
研究设计与样本
- 分别构建CETP和PCSK9血浆蛋白浓度的遗传评分,并组合评估联合 genetically reduced 浓度的关联。
主要发现
- 按每10 mg/dL LDL-C降低计,CETP降低与冠心病风险OR 0.74(95%CI 0.67-0.81),PCSK9降低OR 0.75(95%CI 0.71-0.79)。
- 多重检验校正后,CETP降低与年龄相关性黄斑变性风险增加相关(OR 1.11,95%CI 1.04-1.19)。
临床怎么用
- 联合抑制CETP和PCSK9可能对现有治疗无法达标的高危患者带来额外获益,尤其在他汀或PCSK9抑制剂基础上。
- 临床使用CETP抑制剂时需关注年龄相关性黄斑变性风险。
局限性
- 研究基于欧洲裔人群,结果外推需谨慎。
- 孟德尔随机化结果需随机对照试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Cholesteryl ester transfer protein inhibition (CETP) has been shown to increase levels of high-density lipoprotein cholesterol (HDL-C) and reduce levels of low-density lipoprotein cholesterol (LDL-C). Current LDL-C target attainment is low, and novel phase 3 trials are underway to investigate whether CETP inhibitors result in reduction of cardiovascular disease risk in high-risk patients who may be treated with PCSK9-inhibiting agents. OBJECTIVE: To explore the associations of combined reduction of CETP and PCSK9 concentrations with risk of coronary artery disease (CAD) and other clinical and safety outcomes. DESIGN, SETTING, AND PARTICIPANTS: Two-sample 2 × 2 factorial Mendelian randomization study in a general population sample that includes data for UK Biobank participants of European ancestry. EXPOSURES: Separate genetic scores were constructed for CETP and PCSK9 plasma protein concentrations, which were combined to determine the associations of combined genetically reduced CETP and PCSK9 concentrations with disease. MAIN OUTCOMES AND MEASURES: Blood lipid and lipoprotein concentrations, blood pressure, CAD, age-related macular degeneration, type 2 diabetes, any stroke and ischemic stroke, Alzheimer disease, vascular dementia, heart failure, atrial fibrillation, chronic kidney disease, asthma, and multiple sclerosis. RESULTS: Data for 425 354 UKB participants were included; the median (IQR) age was 59 years (51-64), and 229 399 (53.9%) were female. The associations of lower CETP and lower PCSK9 concentrations with CAD are similar when scaled per 10-mg/dL reduction in LDL-C concentrations (CETP: odds ratio [OR], 0.74; 95% CI, 0.67 to 0.81; PCSK9: OR, 0.75; 95% CI, 0.71 to 0.79). Combined exposure to lower CETP and PCSK9 concentrations was associated with an additive magnitude with lipids and all outcomes, and we did not observe any nonadditive interactions, most notably for LDL-C (CETP: effect size, -1.11 mg/dL; 95% CI, -1.40 to -0.82; PCSK9: effect size, -2.13 mg/dL; 95% CI, -2.43 to -1.84; combined: effect size, -3.47 mg/dL; 95% CI, -3.76 to -3.18; P = .34 for interaction) and CAD (CETP: OR, 0.96; 95% CI, 0.94 to 1.00; PCSK9: OR, 0.94; 95% CI, 0.91 to 0.97; combined: OR, 0.90; 95% CI, 0.87 to 0.93; P = .83 for interaction). In addition, when corrected for multiple testing, lower CETP concentrations were associated with increased age-related macular degeneration (OR, 1.11; 95% CI, 1.04 to 1.19). CONCLUSIONS AND RELEVANCE: Our results suggest that joint inhibition of CETP and PCSK9 has additive effects on lipid traits and disease risk, including a lower risk of CAD. Further research may explore whether a combination of CETP- and PCSK9-related therapeutics can benefit high-risk patients who are unable to reach treatment targets with existing options.
引用
- Cupido AJ, Reeskamp LF, Hingorani AD, et al. Joint Genetic Inhibition of PCSK9 and CETP and the Association With Coronary Artery Disease: A Factorial Mendelian Randomization Study. JAMA Cardiol. 2022. PMID: 35921096. doi:10.1001/jamacardio.2022.2333
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。